. Each test has its advantages and disadvantages but all make small demands on skilled manpower in the laboratory or the field, use inexpensive materials and easily collected specimens, are reliable and raise few administrative problems.
There are a number of other treatable genetically determined metabolic diseases. It is desirable to detect as many as possible with a single test or, second best, to use the same specimen for different tests. The two chromatographic techniques score heavily in this and the bacterial inhibition assay promnises to 'be adaptable as a 'multiple screen' in the near future. The fundamental economic justification for screening programmes flows from the very uneven levels of demand for medical care between different individuals if they are left to seek treatment at their own discretion. With the present 'ion-demand' approach, some people call for medical care frequently and for the most trivial conditions; others fail to seek medical attention for serious and prolonged disorders. The difficulty is exaggerated by the gradual and often insidious onset of many common degenerative diseases which makes it hard for even the most intelligent to know whether treatment is justified. Screening for early signs or symptoms of serious illness can theoretically provide an alternative approach which is much more likely to select for treatment those who can most benefit from it.
The cost of such a screening programme is affected by at least four factors. First, the cost of the screening tests themselves, in terms of equipment, materials and manpower. Second, the cost of contacting the desired public, and ensuring that they attend for examination. This, in turn, will depend on the location of the screening, on how comprehensively the population is to be covered and on how many different tests are carried out simultaneously. Third, the specificity of the tests; that is, the number of 'false positives' which will subsequently require needless investigation. Finally, the incidence and duration of onset of the disease, which between them determine the frequency with which the same population must be rescreened, It is worth pointing out that the comprehensive Kaiser Permanente screening programme, covering a wide range of tests, costs approximately £10 per person examined. If this cost is multiplied by the population of Britain it would amount to a total of £500 million, which equals the sum that it is suggested would 'solve the financial problems of the National Health Service'! The benefits derived from a screening programme also depend on several factors. First, the seriousness of the disease for the individual and the community. Second, the prevalence of the disease, which will determine the number of cases detected by a given number of examinations. Third, the sensitivity of the tests, which will determine the proportion of the total number of cases which will be brought to treatment. Finally, and by far the most important, the extent to which the prognosis of the disease can be affected by treatment after it is detected. There is no benefit at all -and consequently no purpose in screeningif treatment does not improve the prognosis, or if it is unacceptable to the patient.
As with all medical care, the benefits are frequently social and personal rather than economic. Very large financial savings resulted from the detection and treatment of tuberculosis, because it affected mainly young adults. However, by contrast, if heart disease, which affects mainly the elderly, could be prevented by early diagnosis it would lead to a drain on the economy rather than a saving. In addition, early diagnosis often causes an increase in treatment costs. It is always cheaper to die untreated than to be brought in for medical care. Certainly some savings are to be expected by controlling certain diseases before they become chronic and disabling, and perhaps by preventing trivial calls on doctors' time. But on balance screening programmes are likely to raise the cost of medical care rather than to reduce it.
As far as the value of screening is concerned, the previous speakers have indicated the doubts and the cautious attitude which are typical at present in Britain. I believe that the disappointments which there have been so far have arisen because we have been unable to separate physiological variations, for example, in blood sugar or haemoglobin levels, from pathological variations. We now know that there is a continuous distribution of values for most physiological parameters, and a variation of 10-20% from the norm for the population as a whole may have little more significance than a similar variation, for example, in height. There may be no more reason to expect everyone to have a haemoglobin level of 100% than there is to expect -all men to measure 5 ft 8 in.
To overcome this problem, the latest work in the United States is concentrating on establishing a set of normal values for each individual and then screening him in future against his own norms. Thus it is possible to measure changes rather than absolute values. It is possible, in both practical and economic terms, to do this now that computers are generally available. Techniques such as this, and multivariant analysis, should make screening a very much more precise tool in the future. If this prediction proves correct, Britain could have a real opportunity to benefit both the health of the people and the national economy by supporting research in the relevant fields of bio-engineering. The automatic analysers and computers on which such screening programmes would depend could form a very valuable, and highly appropriate, export for Britain.
The United States are very active in developing multiphasic screening, although too often they appear to confuse fundamental and necessary research into techniques with casefinding (which is not yet of proven value using existing techniques). In Britain, although some very valuable research is being undertaken, in general, we have tended to neglect the field of screening and early diagnosis. Through doing so we could be losing an opportunity of developing a new medical technology for Britain.
